Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer

30 Jan 2020

Abstract excerpt

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and currently lacks any effective targeted therapy. Since epigenetic alterations are a common event in TNBC, DNA methylation profiling can be useful for identifying potential biomarkers and therapeutic targets. Here, genome-wide DNA methylation from eight TNBC and six non-neoplastic tissues was analysed using Illumina Human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32019179
DOI: 10.3390/ijms21030903

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast CancerPMID 32019179Read ↗

Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast CancerSemantic proximity Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.Semantic proximity Read ↗

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read ↗

Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.Semantic proximity Read ↗

Overexpression of ADAM10 correlates with poor prognosis and immune infiltrates in breast canceSemantic proximity Read ↗

ADAMTS5 modulates breast cancer development as a diagnostic biomarker and potential tumor suppressor, regulating by BAIAP2-AS1, VTI1B, CRNDE, and hsa-miR-135b-3p: integrated systems biology and experimental approachSemantic proximity Read ↗

Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical valueSemantic proximity Read ↗

Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin ASemantic proximity Read ↗

Deciphering The Prognostic Impact of Aberrant DNA Methylation on ANGPT1 Gene in Breast CancerSemantic proximity Read ↗

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancerSemantic proximity Read ↗

Tristetraproline in breast cancer: treat or trick?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.